Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alendronate sodium
Drug ID BADD_D00065
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Marketing Status Prescription; Discontinued
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D00939
MeSH ID D019386
PubChem ID 6331783
TTD Drug ID D09KLR
NDC Product Code 53104-7525; 50090-4692; 76282-682; 69543-130; 63629-7329; 50090-4076; 61919-689; 16714-633; 65862-329; 60429-055; 64980-340; 60723-205; 61919-729; 65862-268; 65862-328; 55111-874; 64980-342; 0115-1680; 69097-224; 60723-207; 65691-0056; 69097-223; 68071-1514; 50090-5677; 50090-2322; 0115-1678; 0115-1676; 70518-0033; 51224-301; 0054-0282; 78206-135; 71205-048; 0115-1679; 68788-7130; 50090-3593; 0115-1681; 50090-3126; 60429-056; 65862-327; 63415-0071; 16714-631; 68071-3171; 50090-5474; 65372-1134; 64980-341; 76282-681; 68071-3340; 68071-4017; 69543-131; 17139-400; 13371-111; 16714-632
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NNaO7P2
CAS Registry Number 129318-43-0
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN.[Na]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Melaena24.07.02.013; 07.12.02.004--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Oesophageal stenosis07.13.02.001--
Oesophageal ulcer07.04.05.002--
Oesophagitis07.08.05.001--
Osteonecrosis24.04.05.004; 15.02.04.007--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Scleritis10.02.01.025; 06.04.07.002--Not Available
Stevens-Johnson syndrome10.01.03.020; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urticaria23.04.02.001; 10.01.06.001--
Uveitis10.02.01.023; 06.04.03.003--
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Adverse event08.06.01.010--Not Available
Erosive oesophagitis07.04.05.004--Not Available
Osteonecrosis of jaw15.02.04.010; 24.04.05.005--
Regurgitation07.01.07.004--Not Available
Perforation08.01.03.058--Not Available
The 2th Page    First    Pre   2    Total 2 Pages